Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

NCT02821000 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC